Court extends pause on pill ruling
Justices ensure, for now, access to abortion drug
WASHINGTON — The Supreme Court extended a pause on a lower-court ruling that had sought to limit access to a commonly used abortion pill, ensuring that the drug, mifepristone, would remain widely available for now.
In a brief order, Justice Samuel Alito announced that the court would extend its stay through Friday evening, giving the court more time to consider the case.
At issue is a ruling by Judge Matthew J. Kacsmaryk of the Northern District of Texas, who in recent weeks had invalidated the Food and Drug Administration’s approval of the pill.
The announcement slows down what has been a muddled and fast-moving landscape for mifepristone, marked by conflicting US District Court decisions and an appeals panel ruling that further complicated the drug’s legal status.
After the Supreme Court overturned the constitutional right to abortion last summer, political and legal battles have centered on medications used for abortions. In some conservative states, lawmakers have targeted abortion pills.
Medication abortion, a twodrug regimen, is typically used in the first 12 weeks of pregnancy. The first drug, mifepristone, blocks progesterone, a hormone that allows a pregnancy to develop, and the second, misoprostol, taken one or two days later, prompts contractions and helps the uterus expel its contents.
The dispute started in Texas in November, when an umbrella group of medical organizations and a few doctors that oppose abortion sued the FDA, challenging its approval of the pill.
In their suit, the antiabortion groups claimed that the FDA did not follow proper protocols when it approved the drug in 2000. The groups said that the agency had also ignored dangers of the drug in the years since.
The FDA, vigorously countering the plaintiffs’ claims, has said that the drug was properly approved more than 20 years ago and that it is very safe. It has cited years of scientific studies that show that serious complications are rare and that less than 1 percent of patients need hospitalization.
The lawsuit was filed in the Amarillo division of the US District Court for the Northern District of Texas, where a single federal judge, Kacsmaryk, an appointee of President Donald Trump, hears cases.
Kacsmaryk, a longtime opponent of abortion, is a former lawyer for First Liberty Institute, a legal group focused on religious liberty cases that has long backed conservative causes.
This month, Kacsmaryk announced a preliminary ruling that invalidated the FDA’s approval of the drug. But the judge said that the agency had a week to seek emergency relief before his ruling would take effect.
Kacsmaryk suffused his ruling with the language of the antiabortion movement, referring to abortion providers as “abortionists” and a fetus or embryo as an “unborn human” or “unborn child.” He appeared to agree with virtually all of the claims made by the antiabortion groups.
Less than an hour later, another federal judge, Thomas O. Rice, who was appointed by President Barack Obama, issued a contradictory ruling in Washington state in a different lawsuit. Rice blocked the FDA from limiting the availability of mifepristone in much of the country.
The Washington state lawsuit, filed by Democratic attorneys general in 17 states and the District of Columbia, is a direct challenge to the Texas case.
The Biden administration immediately appealed the ruling by the federal judge in Texas, and a divided three-judge panel of the US Court of Appeals for the 5th Circuit, based in New Orleans, announced that mifepristone could remain legal and available while the lawsuit makes its way through the courts.
The panel rejected Kacsmaryk’s finding that the FDA’s approval of mifepristone more than 20 years ago was not valid. At the same time, the judges blocked more recent steps by the FDA to make the drug more easily available, including permission to send the pills by mail. Experts said the consequences could be far-reaching, creating more obstacles for a patient’s ability to secure the drug.
The next day, Rice reaffirmed his ruling, ordering the FDA to maintain the status quo in the 18 jurisdictions, sowing further confusion about the availability of the abortion pill.
The dueling orders all but guaranteed that the case would go to the Supreme Court.